Are you interested in biopharmaceutical quality and advanced therapies? We are looking for Specialist to join our Quality Assurance team.
Your main task is to ensure the manufacturing operations in FinVector are conducted according to GMP and regulatory requirements by reviewing and approving GMP documents. The focus is on the QA review of BMRs, testing records, deviations, GMP project documents and risk assessments. You will also be involved with solving manufacturing, testing and quality system related problems.
In order to succeed you need to have a degree in biosciences or related. Moreover, understanding of quality systems and GMP-regulations as well as previous experience in pharmaceutical quality assurance are seen a plus but not mandatory. If you pay precise attention to details but you also easily manage entireties, this job suits you. Furthermore, we hope your way of working is systematic, unprompted and cooperative. All our documentation is in English and the team is international hence you need to communicate fluently both in written and spoken English.
This position is permanent. We hope that you are able to start to work in December or January.
We offer you an active and lively work community with highly skilled and experienced colleagues in gene therapy manufacturing. We provide you a wide occupational health-care and we support your well-being by ePassi-account. Furthermore, we will continue to support your personal development.
Apply by 30th November!
For more information about the position, phone Stefan Weber, QA Manager, Operations tel. +358 444304739. You’ll reach Stefan on weekdays between 10-16.
What we are looking for
- suitable professional profile
- English skills
- extensive occupational health-care
- ePassi wellbeing benefit
- physical and cultural free-time activities
FinVector Oy is a growing pharmaceutical company authorized by FIMEA, following the procedure of Good Manufacturing Practice (GMP). FinVector is internationally recognized and is a pioneer in its operational field. FinVector works on the cutting-edge biopharmaceuticals and we’ve invested into building state-of-the-art development and GMP facilities for Viral Vector and Cell Therapy platforms including vaccines. Our research and development agenda is focused on the most commonly used gene therapy vectors: adenoviral, adeno-associated viral (AAV) and lentiviral vectors and innovative cell therapies. FinVector offers a versatile and responsible work environment and the work is done together with a group of professionals from various fields. FinVector is owned by Ferring Ventures and we are located in Kuopio, Finland.